Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

NGR016: Randomized Phase II Study Evaluating Two Doses of NGR-hTNF Administered Either as Single Agent or in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma (STS)

The main objective of the trial is to document the preliminary antitumor activity of two doses of NGR-hTNF administered either alone or in combination with doxorubicin in locally advanced or metastatic soft-tissue sarcoma (STS) patients untreated or previously treated with one or more prior systemic regimen.

Study Overview

• Status: Completed
• Conditions: Metastatic Adult Soft Tissue Sarcoma
• Intervention / Treatment: Drug: low-dose NGR-hTNF; Drug: high-dose NGR-hTNF; Drug: Doxorubicin

Detailed Description

Considering the safety/toxicity profile of NGR-hTNF characterized by mild-to-moderate constitutional symptoms when given either every three weeks or weekly both at low (0.8 µg/m^2) and high dose (45 µg/m^2); the reversibility of these adverse events generally occurring only during the infusion time; the absence of overlapping toxicities with chemotherapeutic agents; and the safety and preliminary antitumor activity observed in phase Ib trial with doxorubicin, seems justified to evaluate in a randomized 4-arm phase II trial the preliminary antitumor activity of two doses of NGR-hTNF (0.8 µg/m^2 and 45 µg/m^2) administered weekly either alone or in combination with a standard dose of doxorubicin (60 mg/m^2 every three weeks).

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Phase 2

Contacts and Locations

Study Locations

• France
  • Lyon, France, 69373
    • Centre Léon Bérard
  • Villejuif, France, 94805
    • Institut de Cancerologie Gustave Roussy
• Italy
  • Bologna, Italy, 40136
    • Istituto Ortopedico Rizzoli
  • Milan, Italy, 20133
    • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
  • Pavia, Italy, 27100
    • IRCCS Policlinico S. Matteo
  • Rome, Italy, 00128
    • Università Campus Bio-Medico
• United Kingdom
  • Wirral
    • Bebington, Wirral, United Kingdom, BA11 3
      • Clatterbridge Centre for Oncology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients ≥ 18 years
• Histologically-proven, locally advanced, or metastatic STS (excluding extraosseus Ewing sarcoma)
• Patients not amenable to surgery, radiotherapy, or combined-modality therapy with curative intent
• Patients untreated or previously treated with one or more systemic regimen
• ECOG Performance status 0-2 (Appendix A)
• At least one untreated (not previously irradiated) target lesion that could be measured in one dimension, according to RECIST criteria
• A life expectancy of 12 weeks or more

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

  • Neutrophils > 1.5 x 109/L and platelets > 100 x 109/L
  • Bilirubin < 1.5 x ULN
  • AST and/or ALT < 2.5 x ULN in absence of liver metastasis or < 5 x ULN in presence of liver metastasis
  • Serum creatinine < 1.5 x ULN
  • Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min

• Patients may have had prior treatment providing the following conditions are met before treatment start:

  • Surgery and radiation therapy: wash-out period of 14 days
  • Systemic therapy: wash-out period of 21 days
  • Patients must give written informed consent

Exclusion Criteria:

• Patients may not receive any other investigational agents while on study
• Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
• LVEF < 55% (only for patients candidate for doxorubicin treatment)
• Uncontrolled hypertension
• Prolonged QTc interval (congenital or acquired) > 450 ms
• History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy) or history of stroke
• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
• Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
• Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A: low-dose NGR-hTNF; 0.8 mcg/m² of NGR-hTNF	Drug: low-dose NGR-hTNF; NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs; Other Names: NGR-hTNF
Experimental: B: high-dose NGR-hTNF; 45 mcg/m² of NGR-hTNF	Drug: high-dose NGR-hTNF; NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs; Other Names: NGR-hTNF
Experimental: C: low-dose NGR-hTNF + doxorubicin; 0.8 mcg/m² of NGR-hTNF + doxorubicin	Drug: low-dose NGR-hTNF; NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs; Other Names: NGR-hTNF; Drug: Doxorubicin; Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
Experimental: D: high-dose NGR-hTNF + doxorubicin; 45 mcg/m² of NGR-hTNF + doxorubicin	Drug: high-dose NGR-hTNF; NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs; Other Names: NGR-hTNF; Drug: Doxorubicin; Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-Free Survival (PFS)	Defined as the time from the date of randomization until disease progression, or death	every 6-12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive	every 6-12 weeks
Safety and Toxicity according to NCI-CTCAE criteria (version 4.02)	To evaluate safety and toxicity profile related to NGR-hTNF	during the study
Duration of Disease Control	Measured from the date of randomization until disease progression, or death due to any cause	every 6-12 weeks
Response rate	Measured both according to RECIST criteria and by FDG-PET	every 6-12 weeks
Tumor response	Evaluated by a centralized review of changes in tumor density on CT scan and/or perfusion MRI	every 6-12 weeks

Collaborators and Investigators

• Sponsor: AGC Biologics S.p.A.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2010
• Primary Completion (Actual): May 1, 2016
• Study Completion (Actual): May 1, 2016

Study Registration Dates

• First Submitted: June 7, 2007
• First Submitted That Met QC Criteria: June 7, 2007
• First Posted (Estimate): June 8, 2007

Study Record Updates

• Last Update Posted (Actual): August 29, 2018
• Last Update Submitted That Met QC Criteria: August 27, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: NGR-hTNF; Doxorubicin; Soft Tissue Sarcoma
• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Antibiotics, Antineoplastic; Doxorubicin
• Other Study ID Numbers: NGR016; 2010-018851-88 (EudraCT Number)